1. Background {#sec72155}
=============

Leptospirosis is a zoonotic infection in humans and animals caused by Leptospira species of the spirochete family ([@A16030R1]). There are two stages in the disease process. The first phase occurs during the active leptospira infection named as bacteriemic or septicemic phase. In this phase, flu-like symptoms (including fever, severe headache, myalgia, chills, nausea and vomiting, conjunctival suffusion, abdominal pain, anorexia, coughing and sore throat) occur for more than 5-7 days. The second phase, immunologic, occurs immediately after the bacteriemic phase or 1-3 days after asymptomatic period. Patient\'s symptoms vary in this phase. Many patients have mild fever, headache, vomiting and rash. Aseptic meningitis is most common in the second phase. Ten percent of patients with leptospirosis are affected by a severe form of disease or Weil\'s syndrome (with a mortality rate of 5-40%) ([@A16030R2]). Common symptoms of this syndrome are due to liver, kidney and blood vessels involvement. Symptoms of this severe disease occur after 3 to 7 days and include persistent jaundice, decreased urine output, anemia, rash, hypotension, shock, changes in consciousness, skin and mucosal hemorrhagic lesions and pulmonary hemorrhage ([@A16030R1]-[@A16030R6]). On entering the body, there is widespread hematogenous dissemination and penetration of tissue barriers, including invasion to the central nervous system and aqueous humor of the eye. Transendothelial migration of spirochetes is facilitated by a systemic vasculitis, accounting for a broad spectrum of clinical illness ([@A16030R2], [@A16030R7]). Severe vascular injury can be developed, leading to pulmonary hemorrhage, ischemia of the renal cortex and tubular-epithelial cell necrosis, and destruction of the hepatic architecture, resulting in jaundice and liver cell injury, with or without necrosis ([@A16030R2], [@A16030R8]-[@A16030R11]). Immune-mediated mechanisms have been postulated to affect the severity of symptoms and immune mechanisms, including circulating immune complexes, anticardiolipin antibodies, and antiplatelet antibodies, but their significance has not been proven yet ([@A16030R2]). Old age, pneumonia, renal failure, and thrombocytopenia are associated with a bad prognosis ([@A16030R1]). Thrombocytopenia occurs in the absence of disseminated intravascular coagulation and may accompany progressive renal dysfunction ([@A16030R2]).

2. Objectives {#sec72156}
=============

In this study, we investigated the role of corticosteroids to improve thrombocytopenia due to leptospirosis.

3. Patients and Methods {#sec72157}
=======================

This study was a randomized double-blind clinical trial. This study was approved by the Ethics Committee of Mazandaran University of Medical Sciences (Code No: 9186, Date: December 19, 2012). The sample size in each group was calculated based on previous studies including that performed by Villanueva et al. ([@A16030R12]). The sample size was calculated as 22 based on the following formula, but we enrolled 56 patients.

.

Totally, 187 patients were admitted as leptospirosis based on clinical and epidemiologic criteria in Razi Hospital of Ghaemshahr, north of Iran from August 2011 to September 2013 (two years) (serology tests had not positive results in all cases, those patients diagnosed clinically with false negative serology results were excluded). Razi Hospital is a governmental and teaching hospital with 200 beds. Infectious disease ward is a referral ward in Mazandaran province. Thrombocytopenia was classified to mild (PLT \< 150000), moderate (PLT \< 100000) and severe (PLT \< 50000). Platelet count had normal findings in 17 patients and 98 cases had mild thrombocytopenia and thus excluded. The remaining 72 patients with moderate to severe thrombocytopenia were enrolled. Patients who met the inclusion criteria were randomized to control and treatment groups. We applied simple randomization method. The treatment group received corticosteroid (prednisolone 1 mg/kg/day) in addition to antibiotic therapy (ceftriaxone 1 g/Iv/daily) until improvement of thrombocytopenia or for a maximum one-week and the control group received the same dosage of antibiotics, but received placebo instead of corticosteroid during this period. Exclusion criteria were patients with negative MAT or those with any health-threatening complications caused by corticosteroid or patients who had previous intake of steroids or other antibiotics two weeks or less prior to the diagnosis of disease and patients whom their clinician did not administered steroids due to some compelling factors like hypersensitivity to steroids, and finally those who were not willing to participate. Sixteen patients due to absence of serologic evidence (MAT had negative results) were excluded and the final analysis was performed on 56 patients in two divided groups. Statistical analysis was performed by independent T-test, Chi-Square, Kaplan-Meier, Log Rank and Breslau using SPSS software (version 13). To confirm the diagnosis of leptospirosis by MAT, 10mL blood sample of each patient was obtained. Serum was separated immediately and poured into a sterile polypropylene tube and sent to the Reference Laboratory of Hisarak while maintaining the cold chain. Patients were visited daily and monitored closely. Laboratory changes in patients, including platelet count were check daily. Patients were followed up until discharge ([Tables 1](#tbl18372){ref-type="table"} and [2](#tbl18373){ref-type="table"}).

###### Patients Characteristics

  Characteristics                    No.
  ---------------------------------- -----
  **Suspected Patients**             187
  **Thrombocytopenia**               
  Negative                           17
  Positive                           170
  **Severity of Thrombocytopenia**   
  Mild                               98
  Moderate & severe                  72
  **Serology**                       
  Negative                           16
  Positive                           56
  **Groups**                         
  Case                               28
  Control                            28

###### Distribution of Patients in Moderate and Severe Subgroups

  Thrombocytopenia   Case   Control   Total
  ------------------ ------ --------- -------
  **Moderate**       15     19        34
  **Sever**          13     9         22
  **Total**          28     28        56

4. Results {#sec72158}
==========

Patients' age in the two groups (cases and controls) was compared using independent T-test, which had no significant difference (P = 0.254). The average age in case group was 49.75 ± 8.45 and 46.68 ± 11.26 years in the control group. Gender was assessed using Chi-Square test, which revealed no statistical difference between the two groups (P = 0.789). Treatment group included 14 females and 14 males and control group 13 females and 15 males. Time needed for the improvement of thrombocytopenia was evaluated in the two groups using Kaplan-Meier and Log Rank Test. The treatment group required a mean duration of 4.41 ± 0.197 days and the control group 5.72 ± 0.318 days. The treatment group had a median of 4 ± 0.215 days and the control group 5 ± 0.255 days (Log Rank was 8.625), which was statistically significant (P = 0.003) (degree of freedom (DF) = 1) ([Figure 1](#fig13828){ref-type="fig"} and [Table 3](#tbl18374){ref-type="table"}).

![Survival Function Regarding Required Duration for the Improvement of Thrombocytopenia in the Two Groups](ircmj-16-10-16030-i001){#fig13828}

Duration of hospitalization in the two groups was compared using Kaplan-Meier, Log Rank and Breslau Test. The treatment group had a mean of 5.24 ± 0.244 days and the control group 6.23 ± 0.329 days. The treatment group had a median of 5 ± 0.221 days and the control group 6 ± 0.297 days (Log Rank was 4.825); therefore, there was a significant difference between them (P = 0.028), DF = 1 and Breslau = 4.916 with DF = 1 and P = 0.027 ([Figure 2](#fig13829){ref-type="fig"} and [Table 3](#tbl18374){ref-type="table"}).

![Survival Function Regarding Duration of Hospitalization in the Two Groups](ircmj-16-10-16030-i002){#fig13829}

There was no significant difference between the two groups regarding mortality rate, intubation, platelet count, duration of ICU admission, and pulmonary, renal or hepatic involvement. In our study, five patients expired including two patients in the case group (one in moderate thrombocytopenia subgroup and the other in the severe thrombocytopenia subgroup) and three in the control group (all in the severe thrombocytopenia subgroup). One died due to acute renal failure and others died due to multiorgan failure. The two groups were divided into two subgroups according to the severity of thrombocytopenia ([Table 2](#tbl18373){ref-type="table"}) as moderate (50000 \< PLT \< 100000) and severe (PLT \< 50000). The two subgroups of moderate and severe thrombocytopenia were compared regarding required time for thrombocytopenia improvement; P-values in moderate and severe subgroup were 0.016 and 0.001, respectively, which was statistically significant. Besides, duration of hospital stay was compared between moderate and severe subgroups using Brislow test; P-values were 0.06 and 0.006, respectively, there was no significant differences in moderate group, but the group there were severe a statistical difference was significant ([Table 3](#tbl18374){ref-type="table"}). There was no significant difference between the two subgroups (moderate and severe thrombocytopenia) between the case and control groups regarding mortality, intubation, length of stay in ICU, pulmonary, renal or hepatic involvement and platelets count.

###### Statistical Analysis Regarding Improvement of Thrombocytopenia and Length of Hospitalization

  Group                                                           Mean/M. Rank   Median   Breslau/ Log Rank   P Value
  --------------------------------------------------------------- -------------- -------- ------------------- ---------
  **Duration** ^**[a](#fn15410){ref-type="table-fn"}**^                                   8.626               0.003
  Case                                                            4.411          4.000                        
  Control                                                         5.722          5.000                        
  Moderate                                                                                5.779               0.016
  Case                                                            4.200          4.000                        
  Control                                                         4.947          5.000                        
  Severe                                                                                  12.035              0.001
  Case                                                            4.641          5.000                        
  Control                                                         7.563          7.000                        
  **Hospitalizationb** ^**[b](#fn15411){ref-type="table-fn"}**^                           4.916               0.027
  Case                                                            5.241          5.000                        
  Control                                                         6.231          6.000                        
  Moderate                                                                                3.546               0.060
  Case                                                            4.800          5.000                        
  Control                                                         5.579          5.000                        
  Severe                                                                                  7.505               0.006
  Case                                                            5.678          6.000                        
  Control                                                         7.875          7.000                        

^a^ Duration, Duration in days required for improvement of thrombocytopenia.

^b^ Hospitalization, length of hospital stay (in days).

###### Demographic Characteristics and Frequency of Clinical and Laboratory Findings in the Groups^[a](#fn15412){ref-type="table-fn"}^

  Group/Analysis Variable                                        Received Corticosteroid Group   Not-received Corticosteroid Group   P-Value   Total Frequency
  -------------------------------------------------------------- ------------------------------- ----------------------------------- --------- -----------------
  **Number of Patients**                                         28                              28                                            56 (100)
  **Moderate Thrombocytopenia**                                  15                              19                                            34 (60.7)
  **Severe Thrombocytopenia**                                    13                              9                                             22 (39.2)
  **Gender**                                                                                                                         0.789     
  Female                                                         14                              13                                            
  Male                                                           14                              15                                            
  **Age**                                                        49.75 ± 8.45                    46.68 ± 11.26                       0.254     
  **Kidney involvement**                                         5 (17.9)                        5 (17.9)                            1.000     
  **Lung involvement**                                           5 (17.9)                        6 (21.4)                            0.737     
  **Liver involvement**                                          9 (32.1)                        12 (42.9)                           0.408     
  **Intubation**                                                 4 (14.2)                        4 (14.2)                            1.000     
  **Mortality**                                                  2 (7.1)                         3 (10.7)                            0.500     
  **ICU admission, Mean Rank**                                   28.02                           28.98                               0.758     
  **Dialysis**                                                                                                                                 
  **Platelet Consumption, Mean Rank**                            27.79                           29.21                               0.568     
  **Duration** ^**[b](#fn15413){ref-type="table-fn"}**^                                                                              0.003     
  Mean                                                           4.41 ± 0.197                    5.72 ± 0.318                                  
  Median                                                         4 ± 0.215                       5 ± 0.255                                     
  **Hospitalization** ^**[c](#fn15414){ref-type="table-fn"}**^                                                                       0.028     
  Mean                                                           5.24 ± 0.244                    6.23 ± 0.329                                  
  Median                                                         5 ± 0.221                       6 ± 0.297                                     
  **Rural**                                                      24 (85.7)                       24 (85.7)                                     48 (85.7)
  **Farmer**                                                     24 (85.7)                       25 (89.2)                                     49 (87.5)
  **Weakness**                                                   28 (100)                        28 (100)                                      56 (100)
  **Fever**                                                      28 (100)                        28 (100)                                      56 (100)
  **Anorexia**                                                   20 (71)                         20 (71)                                       40 (71.4)
  **Myalgia**                                                    25 (89.28)                      24 (85.71)                                    49 (87.5)
  **Arthralgia**                                                 20 (71.42)                      20(71.42)                                     40 (71.4)
  **N/V**                                                        9 (32.1)                        7 (25)                                        16 (28.5)
  **Cough**                                                      6 (21.4)                        5 (17.8)                                      11 (19.6)
  **Headache**                                                   7 (25)                          7 (25)                                        14 (25)
  **Abdominal pain**                                             5 (17.8)                        5 (17.8)                                      10 (17.8)
  **Hemoptysis**                                                 1 (3.5)                         2 (7.1)                                       3 (5.35)
  **Diarrhea**                                                   2 (7.1)                         2 (7.1)                                       4 (7.1)
  **Hypotension**                                                3 (10.7)                        3 (10.7)                                      6 (10.7)
  **Tachypnea**                                                  5 (17.8)                        6 (21.4)                                      11 (19.6)
  **Tachycardia**                                                9 (32.1)                        9 (32.1)                                      18 (32.1)
  **LOC**                                                        2 (7.1)                         3 (10.7)                                      5 (8.9)
  **Fever blister**                                              8 (28.5)                        8 (28.5)                                      16 (28.5)
  **Rash**                                                       5 (17.8)                        5 (17.8)                                      10 (17.8)
  **Suffusion**                                                  11 (39.2)                       12 (42.8)                                     23 (41.0)
  **Icter**                                                      9 (32.1)                        12 (42.8)                                     21 (37.5)
  **LAP**                                                        0                               1 (3.5)                                       1 (1.7)
  **Rales**                                                      4 (14.2)                        4 (14.2)                                      8 (14.2)
  **Abdominal tenderness**                                       5 (17.8)                        6 (21.4)                                      11 (19.6)
  **Splenomegaly**                                               2 (7.1)                         3 (10.7)                                      5 (8.9)
  **Hepatomegaly**                                               0                               1 (3.5)                                       1 (1.7)
  **Muscular tenderness**                                        10 (35.7)                       10 (35.7)                                     20 (35.7)
  **Arrhythmia**                                                 1 (3.5)                         0                                             1 (1.7)
  **Oliguria**                                                   5 (17.8)                        5 (17.8)                                      10 (17.8)
  **EKG Changes**                                                2 (7.1)                         1 (3.5)                                       3 (5.35)
  **CXR Changes**                                                5 (17.8)                        7 (25)                                        12 (21.4)
  **Leukocytosis**                                               6 (21.4)                        8 (28.5)                                      14 (25)
  **Leucopenia**                                                 1 (3.5)                         3 (10.7)                                      4 (7.1)
  **Azotemia**                                                   5 (17.8)                        5 (17.8)                                      10 (17.8)
  **Hyperglycemia**                                              2 (7.1)                         3 (10.7)                                      5 (8.9)
  **Hypoglycemia**                                               0                               0                                             0
  **Hyperkalemia**                                               5 (17.8)                        6 (21.4)                                      11 (19.6)
  **Hypokalemia**                                                5 (17.8)                        5 (17.8)                                      10 (17.8)
  **Hematuria**                                                  5 (17.8)                        7 (25)                                        12
  **ESR, Total mean**                                            30.20 ± 19.323                                                                
  **CRP, Total mean**                                            0.86 ± 0.724 (0-2 plus)                                                       
  **INR, Total mean**                                            1.10 ± 0.128                                                                  
  **BILL-T, Total mean**                                         4.675 ± 4.1387                                                                
  **BILL-D, Total mean**                                         1.996 ± 2.0695                                                                
  **AST, Total mean**                                            114.75 ± 89.278                                                               
  **ALT, Total mean**                                            125.93 ± 91.229                                                               
  **ALK.P, Total mean**                                          374.07 ± 131.135                                                              

^a^ Abbreviations: ICU, intensive care unit; CXR, chest x-ray; N/V, nausea and vomiting; LOC, decreased level of consciousness; LAP, lymphadenopathy; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; INR, international normalized ratio; BILL-T, bilirubin-total; BILL-D, bilirubin-direct; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALK.P, alkaline phosphatase.

^b^ Duration = Duration in days required for the improvement of thrombocytopenia.

^c^ Hospitalization = length of hospital stay (in days).

5. Discussion {#sec72159}
=============

There was no significant difference between the two groups regarding renal, pulmonary or hepatic involvement, intubation, mortality rate and hospitalization duration in ICU. The above situations were not improved with treatment of glucocorticoid. Despite the fact, required duration for the improvement of thrombocytopenia and duration of hospitalization in two groups were different significantly. On the other hand, treatment with glucocorticoid caused more rapid recovery of thrombocytopenia and shorter hospital stay. Corticosteroids have an essential role in the treatment of many immune-associated diseases, such as SLE, rheumatoid arthritis (RA) and ITP. Prednisolone (1 mg/kg/day) is used for the treatment of mild ITP (Immune or Idiopathic Thrombocytopenic Purpura); while, high-dose corticosteroid (steroid pulse therapy) is used for the severe forms ([@A16030R1], [@A16030R13]). Russell Villanueva et al. in the Philippines, performed an investigation on 36 patients with leptospirosis and found no significant reduction in mortality, duration of hospitalization and dialysis rates between the control and steroids groups ([@A16030R12]). Furthermore, a study by Trivedi et al. in India performed on 602 patients showed that renal and liver involvements had no effect on mortality ([@A16030R14]). Similarly, in this study, statistical analysis showed that renal, lung or liver involvements and the severity of thrombocytopenia had no effect on mortality. Contrary to our results, a clinical trial on 30 patients by VV Shenoy et al. in India showed that corticosteroid therapy within 12 hours of pulmonary involvement due to leptospirosis decreased the mortality rate ([@A16030R15]).

Our study showed that corticosteroid therapy decreased hospital stay only in severe subgroup thrombocytopenia (not in the moderate subgroup). To optimally determine whether adjunctive steroid use in leptospirosis is beneficial, an adequately powered randomized control trial with a larger sample size is recommended.
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